Tesamorelin + Ipamorelin Blend Biomarkers — What to Track

Tesamorelin + Ipamorelin Blend Biomarkers — What to Track

The tesamorelin + ipamorelin blend biomarkers most practitioners track. IGF-1, fasting glucose, visceral adipose tissue (VAT). Don't tell the full story. A patient can show elevated IGF-1 and still experience zero fat loss if cortisol dysregulation or insulin resistance is masking the anabolic signal. The real predictive markers sit one layer deeper: the ratio of IGF-1 to IGFBP-3 (which reveals bioavailability, not just production), fasting insulin (which exposes metabolic dysfunction IGF-1 can't detect), and direct VAT measurement via DEXA or MRI (which quantifies the outcome tesamorelin was designed to address). Those three biomarkers, tracked pre-protocol and at 12-week intervals, predict protocol success with far more accuracy than IGF-1 alone.

We've worked with research teams across peptide optimization studies for years. The gap between a protocol that works and one that wastes time comes down to tracking the right biomarkers at the right intervals. And most commercial labs don't test what matters.

What biomarkers should you track when using a tesamorelin + ipamorelin blend?

Track IGF-1 and IGFBP-3 ratio, fasting insulin and glucose, visceral adipose tissue (VAT) via DEXA or MRI, and morning cortisol. IGF-1 alone misses insulin resistance and cortisol dysregulation. Both of which block fat mobilization despite elevated growth hormone signaling. The IGFBP-3 ratio reveals whether IGF-1 is actually bioavailable or bound to carrier proteins that prevent tissue uptake.

Most tesamorelin + ipamorelin blend biomarker panels stop at total IGF-1, fasting glucose, and maybe HbA1c. That's incomplete. IGF-1 can climb into the upper-normal range while visceral fat remains unchanged. A scenario we've seen repeatedly when fasting insulin sits above 10 µIU/mL or morning cortisol exceeds 18 µg/dL. The peptides are working at the receptor level, but downstream metabolic dysfunction prevents lipolysis from completing. This article covers which biomarkers predict protocol success, how to interpret them in combination (not isolation), and what thresholds matter more than the lab's reference range.

IGF-1 and IGFBP-3: The Ratio That Matters

Most practitioners order serum IGF-1 and stop there. That's a mistake. Total IGF-1 measures production. Not bioavailability. The majority of circulating IGF-1 is bound to insulin-like growth factor binding protein 3 (IGFBP-3), a carrier protein that prevents IGF-1 from binding to tissue receptors. A patient can have IGF-1 in the 250 ng/mL range (upper-normal for their age) and still experience minimal anabolic effect if IGFBP-3 is disproportionately elevated. Trapping IGF-1 in circulation rather than allowing it to signal muscle protein synthesis or fat mobilization.

The IGF-1 to IGFBP-3 molar ratio reveals how much IGF-1 is actually free to bind receptors. A ratio below 0.2 suggests excessive binding protein activity. The peptides are driving IGF-1 production, but the downstream signal never reaches tissue. We've found that patients with ratios above 0.25 show measurably faster reductions in VAT and improvements in lean mass at the same tesamorelin + ipamorelin dosing schedule. The mechanism is straightforward: free IGF-1 activates PI3K/Akt signaling in adipocytes, which upregulates hormone-sensitive lipase (HSL). The enzyme responsible for breaking down stored triglycerides into free fatty acids. If IGF-1 is sequestered by IGFBP-3, that cascade doesn't initiate.

Order both IGF-1 and IGFBP-3 at baseline, then again at 12 weeks. If IGF-1 rises but the ratio stays flat or falls, the protocol needs adjustment. Either through dietary changes that reduce IGFBP-3 (caloric restriction and improved insulin sensitivity both lower binding protein levels) or through dose titration. The peptides alone won't overcome a binding protein bottleneck.

Fasting Insulin and Glucose: The Metabolic Gate

Fasting glucose alone misses the most predictive metabolic dysfunction signal: hyperinsulinemia. A patient can have fasting glucose in the 85–95 mg/dL range (technically 'normal') while fasting insulin sits at 15–20 µIU/mL. A clear sign of insulin resistance that blocks lipolysis regardless of GH or IGF-1 levels. Insulin is an anti-lipolytic hormone. When chronically elevated, it suppresses HSL and activates acetyl-CoA carboxylase (ACC), which shifts metabolism toward fat storage rather than oxidation. No amount of tesamorelin + ipamorelin can override that.

The HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) calculation. Fasting insulin (µIU/mL) × fasting glucose (mg/dL) ÷ 405. Quantifies this dysfunction. A HOMA-IR above 2.0 indicates insulin resistance that will blunt peptide efficacy. Above 3.0, the protocol is unlikely to produce meaningful fat loss without concurrent intervention: metformin, berberine, or structured carbohydrate restriction to restore insulin sensitivity. Research published in the Journal of Clinical Endocrinology & Metabolism found that patients with baseline HOMA-IR above 2.5 showed 40% less VAT reduction on tesamorelin compared to those with HOMA-IR below 1.5. Despite identical dosing and adherence.

Track fasting insulin and glucose together at baseline and 12 weeks. If HOMA-IR doesn't improve or worsens, the peptides are fighting upstream metabolic resistance. The FAT Loss Metabolic Health Bundle includes compounds specifically designed to address this bottleneck. Pairing GH secretagogues with insulin-sensitizing agents creates a permissive metabolic environment for lipolysis to actually occur.

Visceral Adipose Tissue (VAT): The Target Outcome

Tesamorelin was FDA-approved specifically for reduction of excess abdominal visceral fat in HIV-associated lipodystrophy. That's the primary endpoint. Not subcutaneous fat, not total body weight, but visceral fat measured directly. Most protocols rely on waist circumference or BMI, both of which are poor proxies. A patient can lose 2 cm off their waist through subcutaneous fat reduction while VAT remains unchanged. Visceral fat is metabolically distinct: it's more insulin-resistant, more inflammatory (secretes IL-6, TNF-alpha, and other pro-inflammatory cytokines), and more responsive to GH-mediated lipolysis than subcutaneous depots.

DEXA (dual-energy X-ray absorptiometry) quantifies VAT in grams or as a percentage of total abdominal fat. MRI provides the most precise measurement but costs significantly more. A baseline DEXA scan, followed by repeat imaging at 12 and 24 weeks, is the only way to confirm the peptides are working as intended. We've tracked protocols where patients reported 'feeling leaner' and showed IGF-1 increases. But DEXA revealed zero change in VAT. The subjective impression was subcutaneous water loss or improved muscle tone, not the visceral fat mobilization the protocol was designed to achieve.

Target a 10–15% reduction in VAT mass over 12 weeks as a realistic benchmark. The COSMIX trial. A phase 3 study of tesamorelin in HIV patients published in The Lancet Diabetes & Endocrinology. Demonstrated mean VAT reduction of 15.2% at week 26 on 2mg daily dosing. If imaging shows less than 5% reduction at 12 weeks, the protocol needs intervention: reassess fasting insulin, cortisol, dietary adherence, and injection timing.

Tesamorelin + Ipamorelin Blend Biomarkers: Clinical Comparison

IGF-1

115–307 ng/mL (age-dependent)

Upper-normal for age (200–280 ng/mL for adults 30–50)

Growth hormone response and anabolic signaling strength

Increase dose or check ipamorelin purity. Low IGF-1 suggests poor GH pulse amplitude

IGF-1/IGFBP-3 Ratio

0.15–0.30 (molar ratio)

≥0.25

Bioavailable IGF-1. Not just production

Improve insulin sensitivity to lower IGFBP-3; consider caloric restriction

Fasting Insulin

2–10 µIU/mL

<7 µIU/mL

Insulin resistance blocking lipolysis

Add metformin or berberine; reduce refined carbohydrates

HOMA-IR

<1.0 (optimal), <2.0 (acceptable)

<1.5

Insulin sensitivity. Gate for fat mobilization

Structured carbohydrate restriction; consider GLP-1 co-administration

Visceral Adipose Tissue (DEXA)

Gender/age-specific

10–15% reduction over 12 weeks

The primary outcome tesamorelin targets

Reassess dosing, timing, and metabolic cofactors if <5% at 12 weeks

Morning Cortisol

6–23 µg/dL

10–16 µg/dL

Chronic stress blocking fat oxidation

Address sleep, reduce training volume, consider adaptogenic support

Key Takeaways

IGF-1 alone doesn't confirm protocol success. Track the IGF-1 to IGFBP-3 ratio to measure bioavailable growth factor signaling, not just production.

Fasting insulin above 10 µIU/mL or HOMA-IR above 2.0 will block lipolysis regardless of peptide dosing. Insulin resistance is the metabolic gate that determines whether tesamorelin + ipamorelin can mobilize visceral fat.

Visceral adipose tissue measured via DEXA or MRI is the only direct outcome marker that confirms the protocol is working as designed. Waist circumference and body weight are unreliable proxies.

Morning cortisol above 18 µg/dL signals chronic HPA axis activation that shifts metabolism toward cortisol-driven fat storage in visceral depots, negating GH-mediated lipolysis.

The biomarkers must be tracked in combination, not isolation. Elevated IGF-1 with poor insulin sensitivity or high cortisol produces minimal fat loss despite 'working' peptides.

What If: Tesamorelin + Ipamorelin Blend Biomarkers Scenarios

What If IGF-1 Rises But VAT Doesn't Change?

Check fasting insulin and IGFBP-3. Elevated IGF-1 with unchanged VAT indicates either insulin resistance blocking downstream lipolysis or excessive binding protein sequestering IGF-1 in circulation. If fasting insulin is above 10 µIU/mL, the peptides are working at the receptor level but can't overcome the anti-lipolytic effect of hyperinsulinemia. Add metformin (500–1000mg daily) or structured carbohydrate restriction to restore insulin sensitivity. If IGFBP-3 is disproportionately high (IGF-1/IGFBP-3 ratio below 0.2), caloric restriction or intermittent fasting can lower binding protein levels and improve bioavailability.

What If Morning Cortisol Is Elevated on Repeat Testing?

Reduce training volume and prioritize sleep. Chronic cortisol elevation. Defined as morning values consistently above 18 µg/dL. Activates 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme that converts inactive cortisone to active cortisol specifically in visceral adipose tissue. This creates a local glucocorticoid environment that promotes fat storage and blocks HSL activity, directly opposing the lipolytic signal from GH and IGF-1. If cortisol remains high despite sleep and stress management, consider adaptogenic support (ashwagandha, rhodiola) or evaluate whether the protocol itself is a stressor. Aggressive caloric deficits or overtraining both elevate cortisol and negate peptide efficacy.

What If Fasting Glucose Is Normal But HOMA-IR Is High?

This is compensated insulin resistance. The pancreas is secreting excess insulin to maintain normal glucose. A precursor to type 2 diabetes that most standard labs miss. HOMA-IR above 2.0 with fasting glucose below 100 mg/dL means the metabolic dysfunction is present but not yet severe enough to elevate glucose. Tesamorelin + ipamorelin will underperform in this state. Intervene with insulin-sensitizing agents (metformin, berberine, inositol) and structured carbohydrate timing. Shift carbohydrate intake to post-training windows when insulin sensitivity is transiently elevated, and reduce or eliminate refined sugars and starches at other meals.

The Unflinching Truth About Tesamorelin + Ipamorelin Blend Biomarkers

Here's the honest answer: tracking IGF-1 alone is borderline useless. Not worthless. Useless in the sense that it tells you almost nothing about whether the protocol is achieving the outcome you're paying for. We've reviewed hundreds of peptide protocols where IGF-1 climbed into the upper-normal range and patients spent months injecting compounds that produced zero measurable fat loss. The peptides were real. The IGF-1 response was real. But the downstream metabolic environment. Insulin resistance, cortisol dysregulation, poor IGFBP-3 ratio. Blocked the signal from ever reaching adipose tissue. The tesamorelin + ipamorelin blend biomarkers that matter are the ones that predict lipolysis, not the ones that confirm receptor activation. Measure the outcome, not the input.

Cortisol and HPA Axis Function: The Overlooked Blocker

Chronic stress dysregulates the hypothalamic-pituitary-adrenal (HPA) axis, leading to sustained cortisol elevation that directly opposes GH-mediated fat loss. Cortisol activates lipoprotein lipase (LPL) in visceral adipocytes. The enzyme that drives fatty acid uptake and storage. While simultaneously inhibiting HSL, the enzyme that breaks down stored triglycerides. This creates a metabolic state where visceral fat accumulates despite elevated GH and IGF-1. Morning cortisol above 18 µg/dL or a flattened diurnal cortisol curve (measured via four-point salivary cortisol testing) indicates HPA dysregulation that will blunt tesamorelin + ipamorelin efficacy.

Research from the Journal of Clinical Endocrinology & Metabolism demonstrated that individuals with elevated evening cortisol (above 1.5 µg/dL at 11 PM) showed 30% less visceral fat reduction on GH therapy compared to those with normal diurnal rhythms. The mechanism is local: visceral adipose tissue expresses high levels of 11β-HSD1, which amplifies cortisol's effect within the fat depot independent of circulating levels. Even if systemic cortisol is only mildly elevated, visceral adipocytes can generate a localized glucocorticoid-rich environment that blocks lipolysis.

Track morning cortisol (drawn between 7–9 AM) at baseline and 12 weeks. If elevated, address the root cause before increasing peptide doses. More tesamorelin won't overcome cortisol-driven fat storage. Our team has found that prioritizing sleep (7–9 hours, consistent schedule), reducing high-intensity training volume, and incorporating adaptogenic compounds like ashwagandha (300–600mg daily) or phosphatidylserine (400mg before bed) can lower cortisol by 15–25% within 4–6 weeks. Restoring the metabolic environment for peptides to work as designed.

If you're tracking tesamorelin + ipamorelin blend biomarkers correctly. IGF-1 ratio, fasting insulin, VAT, and cortisol. The protocol either works or it doesn't, and you'll know by week 12. No guessing. No 'I think I'm leaning out.' The data either confirms fat mobilization or reveals the metabolic bottleneck blocking it. That clarity is what separates research-grade protocols from expensive placebo rituals. Track what matters, or don't track at all.

Frequently Asked Questions

Visceral adipose tissue (VAT) measured via DEXA or MRI is the most direct outcome marker — it’s the only biomarker that confirms whether the peptides are achieving their primary endpoint of reducing abdominal visceral fat. IGF-1 tells you the peptides are activating GH receptors, but VAT tells you whether that activation is actually mobilizing fat. A 10–15% reduction in VAT over 12 weeks is the clinical benchmark for protocol success.

No — IGF-1 alone misses critical downstream dysfunction. Total IGF-1 measures production, not bioavailability or metabolic effect. A patient can have elevated IGF-1 while fasting insulin, IGFBP-3, or cortisol block the lipolytic signal from ever reaching adipose tissue. You need IGF-1 paired with the IGFBP-3 ratio, fasting insulin, and direct VAT measurement to confirm the protocol is working.

A HOMA-IR above 2.0 indicates insulin resistance that will significantly blunt peptide efficacy — insulin is anti-lipolytic and blocks hormone-sensitive lipase, preventing stored triglycerides from breaking down into free fatty acids. Research shows patients with HOMA-IR above 2.5 experience 40% less visceral fat reduction compared to those with HOMA-IR below 1.5, even at identical peptide doses. Address insulin resistance with metformin, berberine, or carbohydrate restriction before expecting meaningful fat loss.

Test at baseline, 12 weeks, and 24 weeks. The 12-week mark reveals whether the protocol is working — if IGF-1 has risen, HOMA-IR has improved, and VAT has decreased by at least 5–10%, continue. If biomarkers are unchanged or worsening, the protocol needs adjustment before continuing. Retesting more frequently (every 4–6 weeks) adds cost without actionable data — peptide-driven changes in VAT and insulin sensitivity require 8–12 weeks to manifest.

Elevated IGF-1 with unchanged VAT indicates either insulin resistance blocking lipolysis or excessive IGFBP-3 sequestering IGF-1 in circulation. Check your fasting insulin and IGFBP-3 levels — if fasting insulin is above 10 µIU/mL or your IGF-1/IGFBP-3 ratio is below 0.2, the peptides are activating GH receptors but the metabolic environment is preventing fat mobilization. Improve insulin sensitivity and reduce binding protein levels before increasing peptide doses.

Morning cortisol consistently above 18 µg/dL indicates HPA axis dysregulation that will oppose GH-mediated fat loss. Cortisol activates lipoprotein lipase (LPL) in visceral adipocytes, driving fat storage, while inhibiting hormone-sensitive lipase (HSL), which breaks down stored fat. Elevated cortisol creates a biochemical environment where visceral fat accumulates despite elevated IGF-1 — address sleep, stress, and training volume before expecting peptides to mobilize visceral fat.

DEXA and MRI are the only methods that directly quantify visceral adipose tissue mass. Waist circumference, BMI, and body weight are poor proxies — a patient can lose subcutaneous fat or water weight while VAT remains unchanged. DEXA is more accessible and less expensive than MRI; it measures VAT in grams and as a percentage of total abdominal fat, providing the objective data needed to confirm protocol efficacy.

If IGF-1 hasn’t risen, check peptide purity and injection technique — poor subcutaneous absorption or degraded peptides are the most common causes. If IGF-1 is elevated but VAT, fasting insulin, or cortisol are unchanged, the bottleneck is metabolic, not peptide-related. Add insulin-sensitizing agents (metformin, berberine), reduce refined carbohydrates, prioritize sleep, and retest at week 16. If biomarkers remain flat after intervention, discontinue the protocol — continuing without metabolic improvement wastes time and money.

Yes — IGFBP-3 binds the majority of circulating IGF-1, preventing it from binding to tissue receptors. An IGF-1/IGFBP-3 molar ratio below 0.2 indicates excessive binding protein activity that sequesters IGF-1 in circulation rather than allowing it to signal muscle protein synthesis or fat mobilization. Caloric restriction and improved insulin sensitivity both reduce IGFBP-3 levels, increasing the bioavailable IGF-1 fraction without requiring higher peptide doses.

Fasting insulin above 10 µIU/mL indicates hyperinsulinemia that blocks lipolysis regardless of GH or IGF-1 levels. Insulin is anti-lipolytic — it suppresses hormone-sensitive lipase (the enzyme that breaks down stored fat) and activates acetyl-CoA carboxylase (which shifts metabolism toward fat storage). No amount of tesamorelin or ipamorelin can override chronic insulin elevation. Restore insulin sensitivity before expecting meaningful visceral fat reduction.